Literature DB >> 10894322

Long-term continuous use of benzodiazepines by older adults in Quebec: prevalence, incidence and risk factors.

M Egan1, Y Moride, C Wolfson, J Monette.   

Abstract

OBJECTIVE: To determine the prevalence and incidence of long-term use of benzodiazepines and to assess patient-, prescriber-, and drug-related risk factors.
DESIGN: Cohort study. PARTICIPANTS: 1,423 community-dwelling older adults in Quebec who participated in the Canadian Study of Health and Aging (CSHA1). MEASUREMENTS: Patient characteristics were obtained from the CSHA1 database. These were linked to provincial health insurance data to ascertain benzodiazepine use and prescriber characteristics. MAIN OUTCOME MEASURE: Use of benzodiazepines for at least 135 of the first 180 days following initiation of use.
RESULTS: Twelve-month prevalence of long-term continuous use, standardized by age and gender to the Quebec population, was 19.8%. Twelve-month cumulative incidence of long-term continuous use was 1.9%. Older patients were more likely to proceed to long-term continuous use.
CONCLUSIONS: Risk of long-term continuous use of benzodiazepines seems to increase with age. This association was found to be independent of gender, health status, anxiety, cognitive status, benzodiazepine type, and physician characteristics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10894322     DOI: 10.1111/j.1532-5415.2000.tb04758.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  22 in total

Review 1.  Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995.

Authors:  Yoko Murphy; Emily Wilson; Elliot M Goldner; Benedikt Fischer
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

2.  Personality and health in middle age as predictors for well-being and health in old age.

Authors:  Pasqualina Perrig-Chiello; Susanne M Jaeggi; Martin Buschkuehl; Hannes B Stähelin; Walter J Perrig
Journal:  Eur J Ageing       Date:  2008-12-09

3.  Long-term sedative use among community-dwelling adults: a population-based analysis.

Authors:  Deirdre Weymann; Emilie J Gladstone; Kate Smolina; Steven G Morgan
Journal:  CMAJ Open       Date:  2017-03-03

4.  Assessment of abuse potential of benzodiazepines from a prescription database using 'doctor shopping' as an indicator.

Authors:  Vincent Pradel; Catherine Delga; Frank Rouby; Joëlle Micallef; Maryse Lapeyre-Mestre
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

5.  Sleep Dysfunction in Alzheimer's Disease and Other Dementias.

Authors:  Susan M. McCurry; Sonia Ancoli-Israel
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

6.  Sedative load among community-dwelling people aged 75 years and older: a population-based study.

Authors:  Heidi T Taipale; J Simon Bell; Maija Uusi-Kokko; Eija Lönnroos; Raimo Sulkava; Sirpa Hartikainen
Journal:  Drugs Aging       Date:  2011-11-01       Impact factor: 3.923

7.  No End in Sight: Benzodiazepine Use in Older Adults in the United States.

Authors:  Donovan T Maust; Helen C Kales; Ilse R Wiechers; Frederic C Blow; Mark Olfson
Journal:  J Am Geriatr Soc       Date:  2016-11-23       Impact factor: 5.562

Review 8.  The Benzodiazepine-Dementia Disorders Link: Current State of Knowledge.

Authors:  Antoine Pariente; Sophie Billioti de Gage; Nicholas Moore; Bernard Bégaud
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

9.  Determinants of chronic benzodiazepine use in the elderly: a longitudinal study.

Authors:  Hendrika J Luijendijk; Henning Tiemeier; Albert Hofman; Jan Heeringa; Bruno H Ch Stricker
Journal:  Br J Clin Pharmacol       Date:  2007-12-17       Impact factor: 4.335

10.  Association between risk factors for injurious falls and new benzodiazepine prescribing in elderly persons.

Authors:  Gillian Bartlett; Michal Abrahamowicz; Roland Grad; Marie-Pierre Sylvestre; Robyn Tamblyn
Journal:  BMC Fam Pract       Date:  2009-01-06       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.